17 years of historical data (2008–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Tonix Pharmaceuticals Holding Corp. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $142M | $75M | $2.4B | $23.9B | $129M | $1.11T | $602.2B | $162.5B | $39.1B | $19.5B | $9.4B |
| Enterprise Value | $49M | $-18826770 | $2.3B | $23.8B | $-48817536 | $1.11T | $602.2B | $162.5B | $39.1B | $19.5B | $9.4B |
| P/E Ratio → | -0.08 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 14.07 | 7.40 | 304.09 | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.23 | 0.53 | 22.38 | 115.48 | 0.59 | 12620.21 | 63946.58 | 6866.96 | 1588.40 | 768.90 | 233.47 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -1.87 | 302.14 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Tonix Pharmaceuticals Holding Corp. earns an operating margin of -1354.3%. Operating margins have expanded from -1523.9% to -1354.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -106.1% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 23.1% | 23.1% | 39.0% | — | — | — | — | — | — | — | — |
| Operating Margin | -1354.3% | -1354.3% | -1523.9% | — | — | — | — | — | — | — | — |
| Net Profit Margin | -1288.3% | -1288.3% | -1501.8% | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -106.1% | -106.1% | -74.6% | -51.8% | -60.2% | -104.0% | -173.0% | -121.6% | -84.5% | -118.4% | -125.9% |
| ROA | -82.0% | -82.0% | -61.4% | -47.2% | -54.4% | -89.5% | -140.0% | -110.6% | -77.9% | -104.2% | -111.0% |
| ROIC | -150.3% | -150.3% | -99.7% | -130.6% | -261.7% | -727.3% | — | — | -576.5% | -212.5% | -380.3% |
| ROCE | -97.6% | -97.6% | -69.0% | -52.5% | -60.0% | -103.3% | -174.3% | -109.0% | -85.1% | -118.5% | -125.9% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $99M exceeds total debt of $5M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.09 | 0.00 | 0.00 | 0.01 | 0.04 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.67 | -0.14 | -0.58 | -0.81 | -0.86 | -1.16 | -1.06 | -1.04 | -0.75 | -0.48 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($99M) exceeds total debt ($5M)
Short-term solvency ratios and asset-utilisation metrics
Tonix Pharmaceuticals Holding Corp.'s current ratio of 6.50x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 6.04x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 7.19x to 6.50x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.50 | 6.50 | 2.53 | 7.19 | 8.71 | 8.96 | 2.72 | 9.81 | 12.44 | 12.83 | 6.97 |
| Quick Ratio | 6.04 | 6.04 | 1.78 | 7.19 | 8.71 | 8.96 | 2.72 | 9.81 | 12.44 | 12.83 | 6.97 |
| Cash Ratio | 5.40 | 5.40 | 1.32 | 6.61 | 8.23 | 7.85 | 2.19 | 9.43 | 11.99 | 12.34 | 6.47 |
| Asset Turnover | — | 0.06 | 0.05 | — | — | — | — | — | — | — | — |
| Inventory Turnover | 0.92 | 0.92 | 0.34 | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 285.81 | 215.67 | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Tonix Pharmaceuticals Holding Corp. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | 0.0% | — | 0.0% | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $2M | $3M | $563 | $3M | $804200 | $162500 | $39100 | $19500 | $9400 |
Compare TNXP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| TNXPYou | $142M | -0.1 | — | — | 23.1% | -1354.3% | -106.1% | -150.3% | — |
| BNTX | $28B | -33.7 | — | — | 80.3% | -47.8% | -3.4% | -10.5% | — |
| MRNA | $21B | -5.8 | — | — | 54.2% | -123.3% | -28.8% | -27.0% | — |
| SMMT | $13B | -11.5 | — | — | — | — | -206.1% | -163.4% | — |
| PCVX | $8B | -11.0 | — | — | — | — | -25.6% | -24.7% | — |
| CDTX | $7B | -8.3 | — | — | 100.0% | -13811.9% | -219.0% | — | — |
| SCNI | $3B | 0.1 | — | — | -88.1% | -1312.8% | 177.4% | -61.1% | — |
| NVAX | $2B | 3.9 | 3.7 | — | 93.5% | 40.3% | — | — | 0.5 |
| VIR | $1B | -2.9 | — | — | 82.9% | -682.7% | -45.7% | -40.3% | — |
| CVAC | $1B | 6.5 | 3.1 | 12.6 | 80.2% | 33.2% | 26.7% | 65.0% | 0.2 |
| VALN | $963M | -55.3 | 26.3 | — | 41.9% | 7.9% | -7.9% | 4.5% | 6.6 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 17 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how TNXP stacks up against sector leader BioNTech SE.
Start ComparisonTonix Pharmaceuticals Holding Corp.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Tonix Pharmaceuticals Holding Corp.'s return on equity (ROE) is -106.1%. The historical average is -106.9%.
Based on historical data, Tonix Pharmaceuticals Holding Corp. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Tonix Pharmaceuticals Holding Corp. has 23.1% gross margin and -1354.3% operating margin.